Anti-aging Neuropeptides Immune Modulators Under research

ARA-290

Also known as: Cibinetide

ARA-290 (Cibinetide) is an 11-amino acid peptide derived from erythropoietin (EPO) that has been modified to lack erythropoietic activity (it does not increase red blood cells). Its primary function is to activate the innate repair receptor (IRR), which triggers potent anti-inflammatory effects and promotes tissue healing and the repair of damaged nerves.

Mechanism of action

Binds specifically to the Innate Repair Receptor (IRR).
Inhibits the production of pro-inflammatory cytokines.
Promotes cell survival and reduces apoptosis in ischemic or damaged tissues.
Stimulates the regeneration of small nerve fibers, effectively treating neuropathies.

Uses & indications

Neuropathy: Treatment of small fiber neuropathy and chronic neuropathic pain.
Autoimmune and inflammatory diseases: Reduction of systemic inflammation.
Tissue recovery: Accelerates post-ischemic healing.

Effects

Significant relief of chronic neuropathic pain, improvement in sensory nerve function, and overall reduction of systemic inflammation without affecting blood pressure or red blood cell mass.

Considerations & contraindications

Highly safe in clinical trials; no consistent severe adverse effects have been reported.
Administered primarily via daily subcutaneous injection.

Regulatory approval

In advanced clinical trials, often considered an orphan drug for specific neuropathies.

Dosage

In clinical protocols, it typically ranges from 2mg to 4mg daily administered subcutaneously for periods of 28 days.

Storage

Lyophilized at -20°C. Reconstituted at 4°C and protect from light.

Technical data

Regulatory status Under research

Molecular weight 1247.4 Da

Half-life Corto, pero desencadena cascadas intracelulares prolongadas

Administration routes Subcutánea